title: Antagonistic role of natural compounds in mTOR-mediated metabolic reprogramming.
abstract: Cells reprogram their metabolism very early during carcinogenesis; this event is critical for the establishment of other cancer hallmarks. Many oncogenes and tumor suppressor genes control metabolism by interplaying with the existing nutrient-sensing intracellular pathways. Mammalian target of rapamycin, mTOR, is emerging as a collector and sorter of a metabolic network controlling upstream and downstream modulation of these same genes. Natural compounds represent a source of anti-cancer molecules with chemopreventive and therapeutic properties. This review describes selected pathways and genes orchestrating the metabolic reprogramming and discusses the potential of natural compounds to target oncogenic metabolic aberrations.
authors: Laboratoire de Biologie Moléculaire et Cellulaire de Cancer, Hôpital Kirchberg 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg.
authors: Claudia
authors: C
authors: Cerella
authors: Laboratoire de Biologie Moléculaire et Cellulaire de Cancer, Hôpital Kirchberg 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg.
authors: Anthoula
authors: A
authors: Gaigneaux
authors: Laboratoire de Biologie Moléculaire et Cellulaire de Cancer, Hôpital Kirchberg 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg.
authors: Mario
authors: M
authors: Dicato
authors: Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Republic of Korea. Electronic address: marcdiederich@snu.ac.kr.
authors: Marc
authors: M
authors: Diederich
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D065150:Cellular Reprogramming / Q000235:genetics; D003474:Curcumin / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D058539:Phosphatidylinositol 3-Kinase / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D011794:Quercetin / Q000494:pharmacology; D000077185:Resveratrol; D015398:Signal Transduction / Q000235:genetics; D013267:Stilbenes / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc; D013267:Stilbenes; D016159:Tumor Suppressor Protein p53; D011794:Quercetin; C546842:MTOR protein, human; D058539:Phosphatidylinositol 3-Kinase; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases; D003474:Curcumin; D000077185:Resveratrol
keywords: Cancer; Metabolism; Natural compounds; mTOR